Figure 7.

Activity of liposomal drug delivery in the BEB-Glioblastoma model. (A) An in vitro BEB-GBM model was developed to mimic the complexity of drug delivery to a brain tumor. This model combined a monolayer of bEnd.3, as the BBB barrier, and the LN229 cell line at the base as the glioblastoma tumour. (B) To evaluate the ability of free PAN to translocate the BEB and its effect on the integrity of the model barrier, PAN was added at increasing concentrations to the apex of the BEB-GBM model and incubated for 24 h. The integrity of the bEnd.3 was measured by determining the translocation of the FD40 fluorescent probe while LN229 viability was determined using WST-1 reagent and OD_450nm measurement following 24 h incubation. (C) PAN encapsulated RG3 and FC5 functionalized liposomes were analyzed in terms of BEB translocation and delivery of PAN to a glioblastoma cell line and compared with non-functionalized unloaded liposomes (Control). Briefly, PAN loaded liposomes were added to the apex of the BEB-GBM model and incubated for 24 h. The cytotoxic effect of PAN in LN229 was determined by adding WST-1 reagent. The values were obtained from duplicates of two independent experiments.